Handelsbanken Fonder AB Trims Stock Position in Illumina, Inc. $ILMN

Handelsbanken Fonder AB lessened its stake in Illumina, Inc. (NASDAQ:ILMN) by 54.3% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 40,400 shares of the life sciences company’s stock after selling 47,932 shares during the period. Handelsbanken Fonder AB’s holdings in Illumina were worth $3,855,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Rise Advisors LLC lifted its position in shares of Illumina by 173.6% during the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 224 shares in the last quarter. Parkside Financial Bank & Trust raised its position in Illumina by 65.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 115 shares in the last quarter. Cullen Frost Bankers Inc. purchased a new position in shares of Illumina in the 2nd quarter valued at about $41,000. NewSquare Capital LLC grew its position in shares of Illumina by 604.9% during the second quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock worth $41,000 after buying an additional 369 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its stake in shares of Illumina by 2,936.8% during the first quarter. Caitong International Asset Management Co. Ltd now owns 577 shares of the life sciences company’s stock worth $46,000 after buying an additional 558 shares during the period. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Price Performance

Shares of ILMN opened at $125.96 on Tuesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $153.06. The stock has a market cap of $19.25 billion, a PE ratio of 15.94, a price-to-earnings-growth ratio of 2.34 and a beta of 1.42. The firm has a fifty day moving average price of $105.72 and a 200 day moving average price of $98.01.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.18. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the prior year, the company earned $1.14 earnings per share. The company’s revenue was up .4% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, sell-side analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Upgrades and Downgrades

ILMN has been the subject of a number of recent research reports. UBS Group lifted their price target on shares of Illumina from $110.00 to $120.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. Morgan Stanley raised their price objective on shares of Illumina from $100.00 to $105.00 and gave the company an “equal weight” rating in a report on Monday, August 4th. Daiwa Capital Markets cut shares of Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 price objective for the company. in a research report on Tuesday, August 12th. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Finally, Canaccord Genuity Group lifted their price target on Illumina from $105.00 to $112.00 and gave the stock a “hold” rating in a report on Friday, October 31st. Five investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $115.00.

Insiders Place Their Bets

In other Illumina news, Director Scott Gottlieb purchased 500 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The shares were purchased at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the purchase, the director directly owned 12,523 shares in the company, valued at $1,529,433.99. This represents a 4.16% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.60% of the company’s stock.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.